Virtu Financial’s FibroBiologics FBLG Stock Holding History

Virtu Financial’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-743	Closed	-$30K	–	2142
2024 Q4	$30K	Buy	+743	New	+$39.9K	﹤0.01%	1239

Other funds holding FBLG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OAS

Optivise Advisory Services Franklin, Tennessee $197M AUM 26.07% 1-Year Est. Return

RCM

Requisite Capital Management Dallas, Texas $537M AUM 12.29% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Virtu Financial's FBLG Position: Q1 2025 in Review

Virtu Financial sold out of FibroBiologics (FBLG) in Q1 2025, closing a stake of 743 shares — an estimated $30K sold.

Virtu Financial first reported a position in FBLG in Q4 2024 and held it in 1 quarter. The position peaked at $30K in Q4 2024. 65 funds tracked by Wall St. Rank hold FBLG as of Q1 2025.

Virtu Financial reported no remaining FibroBiologics position as of Q1 2025 after selling out during the quarter.
Virtu Financial sold 743 FibroBiologics shares in Q1 2025, an estimated $30K.
Virtu Financial first reported a position in FibroBiologics in Q4 2024 and held it in 1 quarter.
Virtu Financial's FibroBiologics position peaked at $30K in Q4 2024.
65 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2025.

Based on Virtu Financial's 13F filing for Q1 2025, filed 12 May 2025.